← Retour au Screener

Sector: Santé
Open in Terminal → GN.COLive chart · Key metrics · News · Smart money

GN Audio

GN.CO Large Cap

Healthcare · Medical Devices

Mis à jour: Jun 18, 2026, 22:21 UTC

88,56 €
-0.27% aujourd'hui
52W: 85,12 € – 125,90 €
52W Low: 85,12 € Position: 8.4% 52W High: 125,90 €

Price Chart

Indicateurs clés

P/E Ratio
49.2x
Cours/Bénéfice
Forward P/E
16.27x
P/E prévisionnel
P/S Ratio
0.78x
Cours/Ventes
EV/EBITDA
15.04x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
11,3 Md €
Capitalisation boursière
Croissance du CA
-8.2%
Croissance du CA sur un an
Marge bénéficiaire
-2.25%
Marge nette
ROE
2.97%
Rentabilité des capitaux propres
Beta
1.38
Sensibilité au marché
Positions vendeuses
% du flottant vendu à découvert
Volume moyen
656,314
Volume quotidien moyen

Valuation Analysis

Signal
Overvalued
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
12 analysts
Avg. Price Target
115,12 €
+29.99% upside
Target Range
80,65 € – 131,80 €

About the Company

Sector: Healthcare Industry: Medical Devices Country: Denmark Employees: 7,736 Exchange: CPH

GN Audio en bref

GN Audio (GN.CO) is currently trading at 88,56 € with a market capitalization of 11,3 Md €. The trailing P/E ratio stands at 49.2x, with a forward P/E of 16.27x. The 52-week range spans from 85,12 € to 125,90 €; the current price is 29.7% below the yearly high. Year-over-year revenue growth stands at -8.2%.

💰 Dividende

GN Audio currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

12 analystes évaluent GN Audio (GN.CO) au consensus : None. L'objectif de cours moyen est de 115,12 €, soit un potentiel de +29.99% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 80,65 € à 131,80 €.

GN Audio : la thèse d'investissement en détail

GN Audio (GN.CO) operates in the Healthcare — specifically Medical Devices — and is headquartered in Denmark. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -8.2% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

À surveiller

  • The forward P/E of 16.27x is meaningfully below the trailing 49.2x — analysts expect earnings to step up; the next earnings release is the test.
  • The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
  • The analyst consensus price target implies 29.99% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Marge brute élevée de 54.41% — signe d'un pouvoir de fixation des prix
Points faibles
  • CA en contraction (-8.2% sur un an)
  • Actuellement non rentable
  • Actuellement jugée surévaluée
  • Free cash flow négatif

Aperçu technique

MM 50 jours
96,82 €
-8.53% vs. cours
MM 200 jours
103,53 €
-14.46% vs. cours
Sous le plus haut 52s
−29.7%
125,90 €
Au-dessus du plus bas 52s
+4%
85,12 €

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.38 · Élevé
Évolue plus que le marché global
Dette/Capitaux propres
98.4 · Modéré
Dette totale / capitaux propres

The data points to market-like volatility.

Trading Data

50-Day MA: 96,82 €
200-Day MA: 103,53 €
Volume: 421,716
Avg. Volume: 656,314
Short Ratio:
P/B Ratio: 1.27x
Debt/Equity: 98.4x
Free Cash Flow: -6 248 142 117 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy GN Audio?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut